ArticleClinical rheumatology2025
The relationship between vitamin D receptor (VDR) genomic polymorphisms, disease activity, and functional ability in patients with psoriatic arthritis.
Article in Clinical rheumatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Vitamin D in Cardiovascular Medicine: From Molecular Mechanisms to Clinical Translation.Nutrients · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
INTRODUCTION/
objectivesPsoriatic arthritis (PsA) is a chronic inflammatory rheumatic disease strongly associated with psoriasis. We hypothesized that the presence of variant alleles in VDR may be associated with worse clinical outcomes. The aim of this study was to evaluate a possible association between the FokI and TaqI polymorphisms in the VDR gene and clinical markers of disease activity and functional status in PsA.
methodStudy included 68 patients with PsA. Diagnosis was confirmed according to fulfillment of CASPAR criteria for PsA. Disease activity for peripheral arthritis was evaluated using the DAPSA index; global assessment of disease activity and pain were assessed using VAS. BASDAI was used for the axial form of PsA. Functional ability was assessed by HAQ-DI and FACIT-F. BASFI was used for measuring the functional status of axial involvement. Overall functional mobility was assessed with TUG. Laboratory tests included genotyping of the FokI (rs2228570) and TaqI (rs731236), as well as CRP, ESR, IL-6, and 25(OH)D3. Significance was set at P < 0.05.
resultsSignificant difference in FokI polymorphism was observed for intensity of pain, with the T/T genotype reporting worse outcomes than C/C (P = 0.049). BASDAI showed significant differences (P = 0.026), with T/T genotype having higher values than C/C genotype.
conclusionsFokI polymorphism may have a potential role in modulating disease activity and pain perception in patients with PsA, whereas the TaqI polymorphism appears to have less impact on clinical outcomes. The findings emphasize the need for further research to better understand the genetic impact on disease severity in PsA.
Indexed as
Identifiers
40908383What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.